ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SPPI Spectrum Pharmaceuticals Inc

1.03
0.00 (0.00%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Spectrum Pharmaceuticals Inc NASDAQ:SPPI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.03 1.14 0.9785 0 01:00:00

Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming November 21st Deadline in the Class Action L...

17/11/2016 3:30pm

Business Wire


Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Spectrum Pharmaceuticals Charts.

Law Offices of Howard G. Smith reminds investors of the upcoming November 21, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) securities between February 28, 2013 and September 16, 2016, inclusive (the “Class Period”). Spectrum investors have until November 21, 2016 to file a lead plaintiff motion.

The class action complaint filed on behalf of shareholders alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA previously questioned whether the data from the 611 and 612 Studies were clinically meaningful; (2) the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) as a result, defendants' public statements about Spectrum's business, operations and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you purchased Spectrum shares, you may move the Court no later than November 21, 2016 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com

1 Year Spectrum Pharmaceuticals Chart

1 Year Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

1 Month Spectrum Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock